Status:

RECRUITING

Non-invasive Brain Stimulation to Improve Unsteady Gait in Older Adults (StimGait)

Lead Sponsor:

Hebrew SeniorLife

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Fall

Gait, Unsteady

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

Walking is a complex and continuous task that entails repetitive motions of the body. Relatively high gait variability sensitively predicts falls and cognitive decline in older adults. Previous work h...

Detailed Description

This is a randomized controlled trial to examine the efficacy of a non-invasive brain stimulation intervention of tDCS to improve unsteady gait in older adults. The investigators will enroll 30 older ...

Eligibility Criteria

Inclusion

  • Aged 65 and above.
  • Ability to speak and read English.
  • Ability to walk independently and continuously for at least 1 minute.
  • Elevated gait variability as defined by a coefficient of variation (CoV) about average stride time larger and equal to 0.025 during straight-line walking at preferred speed.

Exclusion

  • More than mild cognitive impairment defined by a Montreal Cognitive Assessment (MoCA) score less than 18.
  • Parkinson's disease, multiple sclerosis, stroke, active brain tumor, or other neurological disorders.
  • Self-reported pain or lower extremity deformity that significantly disrupts walking.
  • Contraindications to MRI or tDCS.
  • An episode of acute illness or exacerbation of a diagnosis that requires hospitalization or active treatment within the past 3 months.
  • Current treatment for congestive heart failure, angina, uncontrolled arrythmia, deep vein thrombosis, or other uncontrolled cardiovascular events.
  • Myocardial infarction, coronary artery bypass grafting, angioplasty, or other cardiac conditions within the past 3 months,
  • Active cancer for which chemo/radiation therapy is being received.
  • Psychiatric co-morbidity including major depressive disorder, schizophrenia, psychosis, or other psychiatric illness.
  • Recent use of any sedating medications (sedatives, anti-psychotics, hypnotics, anti-depressants) or change in medication within the previous month.
  • Chronic vertigo or other diagnosed vestibular disorders.
  • Legal blindness, visual impairments that cannot be corrected with glasses, contact lenses, medicine, or surgery.
  • Those without WiFi access
  • Those who do not plan to live in their current homes for the duration of the study

Key Trial Info

Start Date :

June 3 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06008431

Start Date

June 3 2024

End Date

December 31 2025

Last Update

June 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife

Boston, Massachusetts, United States, 02131